Global Weight Loss Drugs, Supplements And Cosmetics Market
Report Description
Individuals with high BMI have a greater risk of developing diseases such as cancer and diabetes. This holds true for both men and women; and those with BMI above 35 are at the highest risk. However, increasing awareness about obesity is encouraging consumers to seek medical assistance and consultation for weight reduction. The market for weight-loss drugs, cosmetics, and supplements is witnessing a significant growth as these do not involve strict diet or exercise regimens. Top pharmaceutical companies have thus increased R&D investments for anti-obesity drugs with minimal or no side effects.
Table of Contents
1. Market overview
1.1. Market definitions
1.2. Market evolution
1.3. Market characteristics
1.4. Market trends
1.5. Relative risk percentage of chronic disease vs. BMI
1.6. Utility vs. adversity analysis
1.7. Stakeholder analysis
1.8. Key findings
2. Weight Loss Drugs and Supplements Market
2.1. Market drivers
2.2. Market restraints
2.3. Opportunity analysis
2.4. Market forecast (2010 to 2015)
2.5. Market structure and strategic analysis
2.5.1. Prescription drugs
2.5.2. Herbal diuretics and fat burners
2.5.3. 5-HTP
2.5.4. Spirulina supplements (algae tablets)
2.5.5. Cimetidine
2.5.6. Calcium/vitamins & carb blockers
3. Weight Loss Cosmetics Market
3.1. Market drivers
3.2. Market restraints
3.3. Opportunity analysis
3.4. Market forecast (2010 to 2015)
3.5. Market structure and strategic analysis
3.5.1. Slimming creams & serum
3.5.2. Calorie off massage shapers
3.5.3. Other cosmetics
4. Geographic Analysis
4.1. North America
4.2. Europe
4.3. Asia and ROW
5. Competitive Landscape
5.1. Key company analysis
5.2. Recent developments
5.2.1. Mergers and acquisitions
5.2.2. New product launch
5.2.3. Agreements and collaborations.
5.2.4. * Market share
6. Strategic Market Assessment
6.1. R&D efforts by major pharmaceutical companies
6.2. Block buster drugs
6.3. Winning imperatives
6.4. Strategic recommendations
6.5. Strategic conclusion
7. Company profiles
7.1. Abbott Laboratories
7.2. Alizyme Plc
7.3. Amylin Pharmaceuticals, Inc
7.4. AstraZeneca Plc
7.5. F.Hoffmann-La Roche Ltd.
7.6. GlaxoSmithKline Plc
7.7. Sanofi-Aventis SA
7.8. Takeda Pharmaceutical Company Limited
7.9. VIVUS, Inc
7.10. Others
*Subjected to the availability of information
Growth opportunities and latent adjacency in Global Weight Loss D